Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
Pierre Quartier Dit MaireEkaterina AlexeevaTamàs ConstantinVyacheslav ChasnykNico WulffraatKarin PalmbladCarine WoutersHermine I BrunnerKatherine MarzanRayfel SchneiderGerd HorneffAlberto MartiniJordi AntónXiaoling WeiAlan SladeNicolino RupertoKen Abramsnull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Reduction of canakinumab exposure may be feasible in patients who have achieved clinical remission of systemic JIA, but consistent interleukin-1 inhibition appears necessary to maintain this response.
Keyphrases
- juvenile idiopathic arthritis
- disease activity
- open label
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systemic lupus erythematosus
- clinical trial
- rheumatoid arthritis
- prognostic factors
- ulcerative colitis
- randomized controlled trial
- study protocol
- phase ii study
- phase iii
- double blind